Stoke Therapeutics (NASDAQ:STOK) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Stoke Therapeutics (NASDAQ:STOK) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have $23.00 target price on the stock.

According to Zacks, “Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company’s product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. “

STOK has been the subject of several other reports. Cowen reiterated a buy rating on shares of Stoke Therapeutics in a research report on Thursday, August 15th. Canaccord Genuity began coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set a buy rating and a $44.00 price target for the company. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set an overweight rating and a $34.00 price target for the company. Finally, Credit Suisse Group started coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set an outperform rating and a $35.00 price target for the company. Five analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $34.00.

STOK stock traded up $0.12 during trading on Wednesday, hitting $22.37. 5,478 shares of the company traded hands, compared to its average volume of 252,875. The stock’s 50-day moving average is $26.57. Stoke Therapeutics has a 1 year low of $19.21 and a 1 year high of $39.04.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.58). Research analysts anticipate that Stoke Therapeutics will post -2.23 EPS for the current year.

In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp acquired 31,560 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was acquired at an average cost of $21.96 per share, for a total transaction of $693,057.60.

Institutional investors have recently bought and sold shares of the company. Platinum Investment Management Ltd. purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $29,000. Victory Capital Management Inc. purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $73,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $88,000. Morgan Stanley purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $104,000. Finally, KCL Capital L.P. purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $292,000. Institutional investors and hedge funds own 43.43% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Article: Monthly Dividend Stocks

Get a free copy of the Zacks research report on Stoke Therapeutics (STOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.